ENVIOMYCIN SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C25H43N13O10.3H2O4S
Molecular Weight	1665.615
Optical Activity	UNSPECIFIED
Defined Stereocenters	14 / 14
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.NCC[C@@H](O)[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)[C@H]2CCNC(=N)N2.NCC[C@@H](O)[C@H](N)CC(=O)N[C@H]3CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC3=O)=C\NC(N)=O)[C@H]4CCNC(=N)N4

InChI

InChIKey=DZKQVWCTFCSEKF-QOEBQMAPSA-N

InChI=1S/2C25H43N13O10.3H2O4S/c2*26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43;3*1-5(2,3)4/h2*7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48);3*(H2,1,2,3,4)/b2*13-7-;;;/t2*10-,11-,12+,14+,15+,16-,18+;;;/m11.../s1

HIDE SMILES / InChI

Molecular Formula	C25H43N13O10
Molecular Weight	685.69
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	2
Optical Activity	UNSPECIFIED

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4308717
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483

Enviomycin, antimicrobial drug, was isolated in Japan from fermentation broth of Syteptomyces griseoverticillatus var tuberacticus. This drug, a water-soluble, basic peptide, is effective against tubercle bacilli as well as some gram-positive and gram-negative bacteria. It is related to viomycin and cepreomycin in some of its physicochemical properties. It is used for the treatment of Mycobacterium avium caused lung diseases.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Group I intron splicing 2 Target ID: GO:0000372 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7509881	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 83 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6276611 https://www.ncbi.nlm.nih.gov/pubmed/2539957	Curative		Not Provided 511	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Case of multi-drug resistant pulmonary tuberculosis with bilateral cavitary lesions successfully treated by surgical treatment].	2007-11	18078108
[Case of pulmonary multi-drug resistant tuberculosis with left destroyed lung, treated with pneumonectomy].	2007-07	17695788
[A case of pulmonary Mycobacterium fortuitum infection successfully treated with Kampo treatments].	2006-08	16972656

Patents

Sample Use Guides

In Vivo Use Guide

1 g/day three times weekly

Route of Administration: Unknown

In Vitro Use Guide

Enviomycin is bactericidal against Mycobacterium avium strain 13887 with MIC=1.6 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:29:17 GMT 2025` Edited by `admin` on `Mon Mar 31 21:29:17 GMT 2025`
Record UNII	67846BXW65
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TUBERACTIN

Preferred Name

English

ENVIOMYCIN SULFATE

Common Name

English

ENVIOMYCIN SULFATE [MI]

Common Name

English

Enviomycin sulfate [WHO-DD]

Common Name

English

ENVIOMYCIN SULFATE [JAN]

Common Name

English

VIOMYCIN, 1-((3R,4R)-4-HYDROXY-3,6-DIAMINOHEXANOIC ACID)-6-(L-2-(2-AMINO-1,4,5,6-TETRAHYDRO-4-PYRIMIDINYL)GLYCINE)-, (R)-, SULFATE (2:3) (SALT)

Common Name

English

CYCLO((2Z)-3-((AMINOCARBONYL)AMINO)-2,3-DIDEHYDROALANYL-(2S)-2-((4R)-2-AMINO-3,4,5,6-TETRAHYDRO-4-PYRIMIDINYL)GLYCYL-(2S)-2-(((3R,4R)-3,6-DIAMINO-4-HYDROXY-1-OXOHEXYL)AMINO)-.BETA.-ALANYL-L-SERYL-L-SERYL), SULFATE (2:3)

Code

English

Code System Code Type Description

ChEMBL

CHEMBL2146142